ORIC Pharmaceuticals has been granted a patent for compounds that inhibit Polo Like Kinase 4 (PLK4), potentially useful in treating cancer. The patent also covers pharmaceutical compositions and methods of treatment involving these compounds. GlobalData’s report on ORIC Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on ORIC Pharmaceuticals, Peptide pharmacophores was a key innovation area identified from patents. ORIC Pharmaceuticals's grant share as of January 2024 was 24%. Grant share is based on the ratio of number of grants to total number of patents.
The granted patent (Publication Number: US11858915B2) includes a series of claims related to a compound selected from a specific group. The claims outline different variations and aspects of the compound, specifying its characteristics and potential applications. These claims provide a detailed description of the compound's properties, allowing for a comprehensive understanding of its potential uses and benefits in various fields.
Furthermore, the patent also includes a claim related to a pharmaceutical composition containing the compound mentioned in the previous claims. This pharmaceutical composition comprises the specified compound or a pharmaceutically acceptable salt thereof, along with one or more pharmaceutically acceptable excipients. This claim highlights the potential practical application of the compound in the development of pharmaceutical products, indicating its relevance in the healthcare and medical industries. Overall, the patent's claims offer valuable insights into the compound's properties and its potential role in pharmaceutical compositions, paving the way for further research and development in this area.
To know more about GlobalData’s detailed insights on ORIC Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
